Experimental cell therapy targets tough blood cancers
NCT ID NCT05895994
First seen Feb 03, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This early-stage study tested a new treatment called RD13-02, a type of CAR-T cell therapy, in 2 patients with blood cancers (like leukemia or lymphoma) that had come back or stopped responding to standard treatments. The main goal was to see if the treatment was safe and to learn how long the modified cells stay in the body. The therapy targets a protein called CD7 found on the cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Union Hospital, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.